| Title |
Clinical Use of Cannabinoids for Symptom Control in Multiple Sclerosis
|
|---|---|
| Published in |
Neurotherapeutics, October 2015
|
| DOI | 10.1007/s13311-015-0383-5 |
| Pubmed ID | |
| Authors |
William G Notcutt |
| Abstract |
The endocannabinoid system was discovered in 1988 but has received little attention for its potential therapeutic possibilities. That has started to change, and since 2000, a significant number of clinical trials of cannabinoids, principally for the control of spasticity in multiple sclerosis, have been undertaken. These studies have been difficult because of the nature of the disease and have involved patients for whom other therapies have failed or proved inadequate. This paper outlines the background to the use of cannabinoids available and discusses the principles of practice associated with their safe use. The focus has been on nabiximols, being the most studied and the only cannabinoid that has been both adequately researched for use in multiple sclerosis and granted a license by the regulators. However, what has emerged is that the effect for many patients can be much wider than just control of spasticity. Within and outside of neurology there seems to be an expanding range of possibilities for the therapeutic use of cannabinoids. |
X Demographics
The data shown below were collected from the profiles of 6 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Canada | 1 | 17% |
| Unknown | 5 | 83% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 5 | 83% |
| Practitioners (doctors, other healthcare professionals) | 1 | 17% |
Mendeley readers
The data shown below were compiled from readership statistics for 106 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | <1% |
| Unknown | 105 | 99% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 19 | 18% |
| Student > Ph. D. Student | 15 | 14% |
| Student > Master | 14 | 13% |
| Researcher | 10 | 9% |
| Other | 6 | 6% |
| Other | 14 | 13% |
| Unknown | 28 | 26% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 28 | 26% |
| Biochemistry, Genetics and Molecular Biology | 8 | 8% |
| Agricultural and Biological Sciences | 8 | 8% |
| Nursing and Health Professions | 6 | 6% |
| Neuroscience | 6 | 6% |
| Other | 20 | 19% |
| Unknown | 30 | 28% |
Attention Score in Context
This research output has an Altmetric Attention Score of 5. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 13 September 2016.
All research outputs
#7,205,554
of 25,374,917 outputs
Outputs from Neurotherapeutics
#689
of 1,307 outputs
Outputs of similar age
#81,012
of 286,877 outputs
Outputs of similar age from Neurotherapeutics
#13
of 19 outputs
Altmetric has tracked 25,374,917 research outputs across all sources so far. This one has received more attention than most of these and is in the 71st percentile.
So far Altmetric has tracked 1,307 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 18.2. This one is in the 47th percentile – i.e., 47% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 286,877 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 71% of its contemporaries.
We're also able to compare this research output to 19 others from the same source and published within six weeks on either side of this one. This one is in the 31st percentile – i.e., 31% of its contemporaries scored the same or lower than it.